These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 15003887

  • 1. Towards a rational treatment of essential thrombocythemia, despite limited evidence and old prejudices.
    Cazzola M.
    Haematologica; 2004 Feb; 89(2):137-8. PubMed ID: 15003887
    [No Abstract] [Full Text] [Related]

  • 2. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
    Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, Mazzucconi MG, Rodeghiero F, Tura S.
    Haematologica; 2004 Feb; 89(2):215-32. PubMed ID: 15003898
    [Abstract] [Full Text] [Related]

  • 3. Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug.
    Passamonti F, Cazzola M.
    Haematologica; 2004 Nov; 89(11):1284. PubMed ID: 15531447
    [No Abstract] [Full Text] [Related]

  • 4. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Marchioli R, Leone G, Barbui T, GIMEMA CMD-Working Party.
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [Abstract] [Full Text] [Related]

  • 5. How would I manage a case of essential thrombocythaemia presenting with an ischaemic toe.
    McLornan D, McMullin M.
    Hematol Oncol; 2008 Mar; 26(1):3-7. PubMed ID: 17968848
    [Abstract] [Full Text] [Related]

  • 6. The pathogenesis and management of essential thrombocythaemia.
    Green AR.
    Haematologica; 1999 Jun; 84 Suppl EHA-4():36-9. PubMed ID: 10907463
    [No Abstract] [Full Text] [Related]

  • 7. Implications of the consensus definition of clinical resistance and intolerance to hydroxyurea for clinical practice.
    Reilly JT.
    Eur J Haematol Suppl; 2007 Oct; (68):32-4. PubMed ID: 17727564
    [No Abstract] [Full Text] [Related]

  • 8. [Acute myeloid leukemia developing in the course of essential thrombocythemia].
    Fernández MC, Gardelegui I, Capote FJ, Gil JL, Muñoz JA.
    Sangre (Barc); 1996 Oct; 41(5):405-6. PubMed ID: 9026932
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of hydroxyurea in patients with essential thrombocythemia.
    Finazzi G, Barbui T.
    Pathol Biol (Paris); 2001 Mar; 49(2):167-9. PubMed ID: 11317964
    [Abstract] [Full Text] [Related]

  • 10. De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia.
    Hsiao HH, Ito Y, Sashida G, Ohyashiki JH, Ohyashiki K.
    Leuk Res; 2005 Nov; 29(11):1247-52. PubMed ID: 16164981
    [Abstract] [Full Text] [Related]

  • 11. Nail changes after chemotherapy.
    Las Heras G, Juncà Piera J.
    Haematologica; 1998 Aug; 83(8):748. PubMed ID: 9793260
    [No Abstract] [Full Text] [Related]

  • 12. Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with hydroxyurea.
    van den Anker-Lugtenburg PJ, Sizoo W.
    Am J Hematol; 1990 Feb; 33(2):152. PubMed ID: 2301374
    [No Abstract] [Full Text] [Related]

  • 13. Evolving management of essential thrombocythaemia.
    Barbui T.
    Eur J Haematol Suppl; 2007 Oct; (68):22-3. PubMed ID: 17727561
    [No Abstract] [Full Text] [Related]

  • 14. Management of essential thrombocythemia: implications of the medical research council primary thrombocythemia 1 trial.
    Harrison CN.
    Semin Thromb Hemost; 2006 Apr; 32(3):283-8. PubMed ID: 16673283
    [Abstract] [Full Text] [Related]

  • 15. [Hypertriglyceridemia following treatment with interferon alpha in essential thrombocythemia].
    De Salvo L, Plumacher Z, Gómez O, Weir-Medina J, Paz L, Salas D.
    Invest Clin; 1996 Sep; 37(3):177-81. PubMed ID: 8983355
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis.
    Finazzi G, Ruggeri M, Rodeghiero F, Barbui T.
    Blood; 2003 May 01; 101(9):3749. PubMed ID: 12707224
    [No Abstract] [Full Text] [Related]

  • 17. Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations.
    Tefferi A, Passamonti F.
    Am J Hematol; 2009 Oct 01; 84(10):629-30. PubMed ID: 19731306
    [No Abstract] [Full Text] [Related]

  • 18. Essential thrombocythemia.
    Finazzi G, Harrison C.
    Semin Hematol; 2005 Oct 01; 42(4):230-8. PubMed ID: 16210036
    [Abstract] [Full Text] [Related]

  • 19. Association of inv(3)(q21q26) with essential thrombocythemia in transformation.
    Villalón C, Talavera M, Sordo MT, García-Sagredo JM, Lopez J, San Román C, Ferro MT.
    Cancer Genet Cytogenet; 2008 Jul 15; 184(2):122-3. PubMed ID: 18617063
    [No Abstract] [Full Text] [Related]

  • 20. Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.
    Quintás-Cardama A, Pérez-Encinas M, Gonzalez S, Bendaña A, Bello JL.
    Ann Hematol; 1999 Apr 15; 78(4):187-8. PubMed ID: 10348150
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.